-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In clinical practice, a higher incidence of apalutamide-related rash is often observed in Japanese prostate cancer (PC) patients
The study analyzed the data of 68 patients receiving 240 mg apalutamide (SPARTAN: n=34, TITAN: n=28, 56021927PCR1008: n=6) once a day
In summary, the study did not find clinical risk factors for skin rash
Original source:
Hiroji Uemura, et al.
Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study
in this message